UC expert weighs in on current MASH treatment approaches
He says pharmacotherapy pipeline is rapidly evolving
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.
However, the MASH pharmacotherapy pipeline is expanding, said Adam Myer, MD, a faculty member in the University of Cincinnati College of Medicine.
“The MASH pharmacologic landscape has evolved rapidly over the past several years and is now entering a highly active therapeutic era, with FDA-approved therapies alongside a robust pipeline of investigational agents,” Myer, an assistant professor of clinical medicine in the Division of Gastroenterology and Hepatology in the Department of Internal Medicine, told MedCentral.
The U.S. Food and Drug Administration (FDA) approved the first treatment for MASH, resmetirom, in March 2024, followed by semaglutide in August 2025. The MASH pharmacotherapy research pipeline is now dominated by metabolic and incretin-based agents, with additional combination trials and late-stage programs targeting fibrosis, lipogenesis and thyroid hormone signaling.
Myer, who is also a UC Health transplant hepatologist, pointed out that the two FDA-approved medications are indicated for patients with MASH and moderate-to-advanced fibrosis (F2–F3). Thus, “there remains a significant unmet need in patients with cirrhotic (F4) MASH, for which no FDA-approved therapies are currently available,” he said.
Myer emphasized that weight loss is clearly a major driver of histologic improvement in MASH, particularly for steatosis and fibrosis, and underpins much of the benefit observed with GLP-1 therapies.
“Several next-generation dual- and triple-agonists are in development with the potential of greater efficacy in weight reduction and potentially enhanced hepatic outcomes,” he said, “but head-to-head data and long-term safety will ultimately determine their clinical positioning.”
Myer said the MASH therapeutic landscape is expected to evolve toward a more personalized, combination-based treatment paradigm during the next five to 10 years.
“Finally, as more agents become available, clinical algorithms will increasingly incorporate both noninvasive biomarkers and histologic endpoints to guide therapy initiation and escalation and prevent progression to cirrhosis and liver-related complications,” he said.
Featured image at top: Unsplash.
Related Stories
Phenols, found in many products, could upset heart's rhythms
October 7, 2024
Chemicals called environmental phenols include food preservatives, plastics ingredients such as BPA and the parabens in shampoos, so they are ubiquitous in everyday life. Now, University of Cincinnati research suggests that higher exposure to phenols might trigger changes in the heart's electrical system and rhythms.
Struggling with daily HIV meds?
March 23, 2026
For many people living with HIV, staying healthy depends on something deceptively simple: taking a pill every day. But for those navigating unstable housing, stigma, mental health challenges or addiction, that daily routine can be hard to maintain. As Yahoo!Health recently reported, a new study suggests there may be a better option.
UC researchers work to understand how extreme heat impacts older adults
June 1, 2026
University of Cincinnati College of Medicine researchers are working to understand how extreme summer heat affects older adults’ health, as reported by 91.7 WXVU News recently. George Leikauf, PhD, co-director of UC's Center for Collaboration on Climate and Community for Health (C4H) and a professor in the Division of Pulmonary, Critical Care and Sleep Medicine within the Department of Internal Medicine, is leading a study to track the health of older Cincinnatians who live without air conditioning during heat waves.